Results 61 to 70 of about 23,850 (163)

Rosiglitazone and Pioglitazone Alter Aromatase Kinetic Properties in Human Granulosa Cells

PPAR Research, 2011
We have previously reported that, in human granulosa cells, thiazolidinediones rosiglitazone and pioglitazone inhibit estrogen synthesis by interfering with androgen binding to aromatase, without an effect on aromatase mRNA or protein expression.
Takako Araki, Miroslava Varadinova, Michael Goldman, Zev Rosenwaks, Leonid Poretsky, Donna Seto-Young   +5 more
doaj   +1 more source

Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance.

PLoS ONE, 2012
BackgroundEvidence suggests that the PPARγ-agonist insulin sensitizer pioglitazone, may provide potential beneficial cardiovascular (CV) effects beyond its anti-hyperglycaemic function.
Valentina Spigoni, Angela Picconi, Monia Cito, Valentina Ridolfi, Sabrina Bonomini, Chiara Casali, Ivana Zavaroni, Luigi Gnudi, Marco Metra, Alessandra Dei Cas   +9 more
doaj   +1 more source

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open‐Label Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10163-10172, November 2026.
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto, Ayumi Kanamoto, Takao Watanabe, Ryo Yano, Yuki Okazaki, Atsushi Yukimoto, Yoshiko Nakamura, Eiji Takeshita, Teru Kumagi, Yoichi Hiasa   +14 more
wiley   +1 more source

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10780-10794, November 2026.
ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta, L. Donnelly, E. R. Pearson   +4 more
wiley   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, Volume 117, Issue 5, Page 1347-1357, November 2026.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source

Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Ameliorates Chronic Kidney Disease by Enhancing Antioxidative Capacity and Attenuating Angiogenesis in the Kidney of a 5/6 Nephrectomized Rat Model

Cellular Physiology and Biochemistry, 2016
Background/Aims: Pioglitazone is a type of peroxisome proliferator-activated receptor γ agonist and is capable of alleviating renal ischemia-reperfusion injury.
Li Sun, Quan Yuan, Tianhua Xu, Li Yao, Jiangmin Feng, Jianfei Ma, Lining Wang, Changlong Lu, Danan Wang   +8 more
doaj   +1 more source

Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective

Immunology, Volume 179, Issue 3, Page 390-405, November 2026.
Peripheral blood mononuclear cells (PBMCs) from individuals with metabolic syndrome (MetS) who were not using glucose‐and/or lipid lowering medication (GLLM) exhibited a broader cytokine production profile after in vitro antigen‐specific stimulation than PBMCs from individuals with MetS using such medications and from healthy donors.
Isabela Ghetti Macedo Isaac, Carolina do Prado Servian, Fernanda de Oliveira Feitosa de Castro, João Lucas Lima Calandrini de Azevedo, Ronaldo Moraes Preto, Miriam Leandro Dorta, Daniela Espíndola Antunes, Simone Gonçalves Fonseca   +7 more
wiley   +1 more source

Medicinal Chemistry Aspects of Thiazole and Thiazolidine Derivatives as Fundamental Building Blocks to Design New NNRTIs Against HIV‐1 Reverse Transcriptase

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
HIV‐1 reverse transcriptase (HIV‐1 RT) is a polymerase enzyme and a key target in HIV‐1 therapy. The discovery of selective HIV‐1 RT inhibitors has highlighted thiazole scaffolds and their derivatives, thiazolidine‐2‐one and thiazolidine‐2,4‐dione, as promising structures for the rational design of novel non‐nucleoside reverse transcriptase inhibitors (
José Arion da Silva Moura, Matheus Vinicius Guimarães de Melo, Diane Regis Santos do Nascimento, Thaynara Paula Warren Bezerra, Mathieu Métifiot, Patricia Recordon‐Pinson, Maira Galdino da Rocha Pitta, Marina Galdino da Rocha Pitta, Michelly Cristiny Pereira, Marie‐Line Andreola   +9 more
wiley   +1 more source

Cell‐based polygenic risk scores predict clinical progression and prioritize network‐based therapeutic targets in Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract BACKGROUND Late‐onset Alzheimer's disease (AD) exhibits substantial biological heterogeneity. We developed a framework linking cell‐type–specific polygenic risk profiles to precision medicine in AD. METHODS Cell‐based polygenic risk scores (cbPRSs) derived from single‐nucleus RNA‐seq co‐expression networks were evaluated in Alzheimer's Disease
Nathan Sahelijo, Priya Rajagopalan, Lu Qian, Rufuto Rahman, Daniel Goldstein, Sophia I. Thomopoulos, David A. Bennett, Lindsay A. Farrer, Thor D. Stein, Li Shen, Heng Huang, Kwangsik Nho, Andrew J. Saykin, Christos Davatzikos, Paul M. Thompson, Julia TCW, Gyungah R. Jun   +16 more
wiley   +1 more source

Dosing PPARγ Activation With Light Using Fast Relaxing Photoswitches. [PDF]

Angew Chem Int Ed Engl
To achieve spatiotemporal control over PPARγ activity, we designed the fast‐relaxing photoswitchable agonist 6 that selectively activates PPARγ in its light‐induced Z‐state and relaxes within seconds (t1/2 47 s) to the inactive E‐state. This unique profile allowed light‐dosed receptor activation in in vitro settings, enabling biological studies on ...
Knümann L, Rodriguez-Paniagua A, Reynders M, Duensing-Kropp S, Thorn-Seshold O, Morozov V, Marschner JA, Merk D.   +7 more
europepmc   +2 more sources